New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists

Expert Opinion on Investigational Drugs

Volumn 14, Issue 9, 2005, Pages 1085-1097

  Schultze Mosgau, Askan ^a   Griesinger, Georg ^b   Altgassen, Christopher ^b   von Otte, Soeren ^b   Hornung, Daniela ^b   Diedrich, Klaus ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

Abarelix; Cetrorelix; Ganirelix; GnRH agonists; GnRH analogues; GnRH antagonists

Indexed keywords

ABARELIX; ANTIANDROGEN; CETRORELIX; CLOMIFENE; CLOMIFENE CITRATE; DANAZOL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; FOLLITROPIN; GANIRELIX; GESTAGEN; GESTRINONE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; ITURELIX; LUTEINIZING HORMONE; MIFEPRISTONE; NAFARELIN; PLACEBO; PROGESTERONE; RECOMBINANT FOLLITROPIN; SEX HORMONE; SOMATOMEDIN C; STEROID RECEPTOR; TAMOXIFEN; TRIPTORELIN; UNINDEXED DRUG;

ANAPHYLAXIS; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENDOCRINE DISEASE; ENDOMETRIOSIS; ERYTHEMA; FOLLITROPIN RELEASE; GONAD; GONADORELIN RELEASE; GYNECOLOGIC DISEASE; HEADACHE; HEALTH CARE COST; HEMATOMA; HORMONAL REGULATION; HOT FLUSH; HUMAN; HYSTERECTOMY; INFERTILITY THERAPY; INJECTION SITE REACTION; LEIOMYOMA; LUTEINIZING HORMONE RELEASE; META ANALYSIS; MOOD DISORDER; NONHUMAN; OOCYTE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; PREGNANCY RATE; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PRURITUS; REPRODUCTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; UTERUS MYOMA; VAGINAL DRYNESS;

ANIMALS; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; POLYCYSTIC OVARY SYNDROME; PUBERTY, PRECOCIOUS; TECHNOLOGY, PHARMACEUTICAL;

EID: 24344444174     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.9.1085     Document Type: Review

References (117)

1. KNOBIL E: The neuroendocrine control of the menstrual cycle. Recent Prog. Horm. Res. (1980) 36:53-88.
2. ULLOA-AGUIRRE A, TIMOSSI C: Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. Reprod. Biomed. Online (2000) 1:48-62.
3. TSUTSUMI M, ZHOU W, MILLAR P et al.: Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. Mol. Endocrinol. (1992) 6:1163-1169.
4. REINHART J, MERTZ LM, CATT KJ: Molecular cloning and expression of cDNA encoding the murine gonadotropin-releasing hormone receptor. J. Biol. Chem. (1992) 267:21281-84.
5. KAKAR SS, MUSGROVE LC, DEVOR DC, SELLERS JC, NEILL JD: Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem. Biophys. Res. (1992) 189:289-295.
6. SEALFON SC, WEINSTEIN H, MILLAR RP: Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr. Rev. (1997) 18:180-205.
7. STOJILKOVIC SS, REINHART J, CATT KJ: Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr. Rev. (1994) 15:462-499.
8. MILLAR RP, KING JA, DAVIDSON JS, MILTON RC: Gonadotrophin-releasing hormone-diversity of functions and clinical applications. S. Afr. Med. J. (1987) 72:748-755.
9. GRÜNDKER C, GÜNTHERT AR, WESTPHALEN S, EMONS G: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur. J. Endocrinol. (2002) 146:1-14.
10. LIMONTA P, MONTAGNANI-MARELLI M, MORETTI RM: LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin. Investig. Drugs (2001) 10:709-720.
11. HAZUM E, CONN PM: Molecular mechanism of gonadotropin releasing hormone (GnRH) action. I. The GnRH receptor. Endocr. Rev. (1988) 9:379-386.
12. CLAYTON RN: Gonadotrophin-releasing hormone: its actions and receptors. J. Endocrinol. (1989) 120:11-19.
13. KAISER UB, CONN PM, CHIN WW: Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr. Rev. (1997) 18:46-70.
14. EMONS G, NILL J, STURM R, ORTMANN O: Effects of progesterone on gonadotropin-releasing hormone receptor concentration in cultured estrogen-primed female rat pituitary cells. J. Steroid Biochem. Mol. Biol. (1992) 42:831-839.
15. STOJILKOVIC SS, CATT KJ: Expression and signal transduction pathways of gonadotropin-releasing hormone receptors. Recent Prog. Horm. Res. (1995) 50:161-205.
16. CONN PM, CROWLEY WF: Gonadotropin-releasing hormone and its analogues. N. Engl. J. Med. (1991) 324:93-103.
17. KARTEN MJ, RIVIER JE: Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr. Rev. (1986) 7:44-66.
18. RABINOVICI J, ROTHMAN P, MONROE SE, NERENBERG C, JAFFE RB: Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with mionbimal histamine-releasing properties: studies in postmenopausal women. J. Clin. Endocrinol. Metab. (1992) 75:1220-1225.
19. NESTOR JJ, TAHILRAMANI R, HO TL, GOODPASTURE JC, VICKERY BH, FERRANDON B: Potent gonadotropin releasing hormone antagonists with reduced histamine-releasing activity. J. Med. Chem. (1992) 35:3942-3948.
20. DIEDRICH K, DIEDRICH C, SANTOS E et al.: Suppression of the endogenous LH-surge by the LH-RH antagonist Cetrorelix during ovarian stimulation. Hum. Reprod. (1994) 9:788-791.
21. NELSON LR, FUJIMOTO VY, JAFFE RB, MONROE SE: Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-relasing properties (ganirelix). Fertil, Steril. (1995) 63:963-969.
22. RIVIER J, JIANG GC, LAHRICHI SL et al.: Dose relationship between GnRH antagonists and pituitary suppression. Hum. Reprod. (1996) 11(Suppl. 3):133-147.
23. FUJIMOTO VY, MONROE SE, NELSON LR, DOWNEY D, JAFFE RB: Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray. Fertil. Steril. (1997) 67:469-473.
24. CHILLIK C, ACOSTA A: The role of LHRH agonists and antagonists. Reprod. Biomed. Online (2001) 2:120-128.
25. HOWLES C: The place of gonadotropin-releasing hormone antagonists in reproductive medicine. Reprod. Biomed. Online (2002) 4(Suppl. 3):64-71.
26. KUEPKER W, FELBERBAUM R, KRAPP M, SCHILL T, MALIK E, DIEDRICH K: Use of GnRH-antagonists in the treatment of endometriosis. Reprod. Biomed. Online (2002) 5:12-16.
27. ALBANO C, SMITZ J, CAMUS M, RIETHMULLER-WINZEN H, VAN STEIRTEGHEM A, DEVROEY P: Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril. (1997) 67:917-922.
28. FELBERBAUM RE, REISSMANN T, KUEPKER W et al.: Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur. J. Obstet. Gynecol. Reprod. Biol. (1995) 61:151-155.
29. HALMOS G, SCHALLY AV, PINSKI J, VADILLO-BUENFIL M, GROOT K: Down-regulation of pituitary receptors for luteinizing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sciences USA (1996) 93:2398-2402.
30. STANGER YD, YOVICH JL: Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br. J. Obstet. Gynecol. (1985) 92:385-393.
31. LOUMAYE E: The control of endogenous secretion of LH by gonadotrophin releasing hormone agonists during ovarian hyperstimulation for in vitro fertilization and embryo transfer. Hum. Reprod. (1990) 5:357-376.
32. TAN SL, MACONOCHIE N, DOYLE P et al.: Cumulative conception and live birth rates in vitro fertilization with and without the use of long, short, and ultrashort regimes of the gonadotropin-releasing hormone agonist buserelin. Am. J. Obstet. Gynecol. (1994) 171:513-520.
33. MacLACHLAN V, BESANKO M, O'SHEA F et al.: A controlled study of luteinizing hormone-releasing agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization. New Engl. J. Med. (1989) 320:1233-1237.
34. SCHALLY AV, NAIR RM, REDDING TW, ARIMURA A: Isolation of the luteinizing hormone and follicle stimulating hormone-releasing hormone from porcine hypothalami. J. Biol. Chem. (1971) 246:7230-7236.
35. BURGUS R, BUTCHER M, AMOSS M et al.: Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF). Proc. Natl. Acad. Sci. USA (1972) 69:278-282.
36. MATSUO H, BABA Y, NAIR RM, ARIMURA A, SCHALLY AV: Structure of porcine LH and FSH releasing factor. I: the proposed amino acid sequence. Biochem. Biophys. Res. Commun. (1971) 43:1334-1339.
37. KOCH Y, BARAM T, HAZUM E, FRIDKIN M: Resistance to enzymatic degradation of LHRH analogs possessing increased biological activity. Biochem. Biophys. Res. Commun. (1977) 74:488-492.
38. SMITH MA, PERRIN MH, VALE WW: Desensitization of cultured pituitary cells to gonadotropin-releasing hormone: evidence for a post-receptor mechanism. Mol. Cell. Endocrinol. (1983) 30:85-96.
39. SAUER MV, THORNTON MH, SCHOOLCRAFT W. FRISHMAN GN: Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod. Biomed. Online. (2004) 9:487-493.
40. DAYA S: Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst. Rev. (2000) 2:CD001299.
41. TAVMERGEN E, GOKER EN, SENDAG F, SENDAG H, LEVI R: Comparison of short and long ovulation induction protocols used in ART applications according to the ovarian response and outcome of pregnancy. Arch. Gynecol. Obstet. (2002) 266:5-11.
42. KOLIBIANKIS E, ZIKOPOULOS K, SCHIETTECATTE J et al.: Profound LH suppression after GnRH antagonist administration is associated with a higher ongoing pregnancy rate in IVF. Hum. Reprod. (2004) 19:2490-2496.
43. EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS: Committee for proprietary medicinal products. European Public Assessment Report. (1998):CPMP/2979/98.
44. EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS: Committee for proprietary medicinal products. European Public Assessment Report. (2000):CPMP/272/00.
45. DITKOFF EC, CASSIDENTI DL, PAULSON RJ et al.: The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am. J. Obstet. Gynecol. (1991) 165:1811-1817.
46. FELBERBAUM R AND DIEDRICH K: Ovarian stimulation for in vitro fertilization/intracytoplasmatic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists. Hum. Reprod. (1999) 14:207-221.
47. FRYDMAN F, CONEL C, DE ZIEGLER D, TAIEB J, SPITZ IM, BOUCHARD P: Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil. Steril. (1991) 56:923-927.
48. OLIVENNES F, FANCHIN R, BOUCHARD P et al.: The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil. Steril. (1994) 62:468-476.
49. OLIVENNES F, FANCHIN R, BOUCHARD P, TAIEB J, SELVA J, FRYDMAN R: Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum. Reprod. (1995) 10:1382-1386.
50. NG EH, HO PC: Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose. J. Obstet. Gynaecol. Res. (2001) 27:261-265.
51. OLIVENNES F, DIEDRICH K, FRYDMAN R, FELBERBAUM RE, HOWLES CM: Cetrotide Multiple Dose International Study Group; Cetrotide Single Dose International Study Group. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod. Biomed. Online (2003) 6:432-438.
52. KOLIBIANAKIS EM, ZIKOPOULOS K, SMITZ J et al.: Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. Fertil. Steril. (2004) 82:223-226.
53. KOLIBIANAKIS EM, ALBANO C, CAMUS M, TOUNAYE H, VAN STEIRTEGHEM AC, DEVROEY P: Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J. Clin. Endocrinol. Metab. (2003) 88:5632-5637.
54. LUDWIG M, KATALINIC A, BANZ C et al.: Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum. Reprod. (2002) 17:2842-2845.
55. RONGIERES-BERTRAND C, OLIVENNES F, RIGHINI C et al.: Revival of the natural cycles in in vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (cetrorelix): a pilot study with minimal stimulation. Hum. Reprod. (1999) 14:683-688.
56. HWANG JL, HUANG LW, HSIEH BC et al.: Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum. Reprod. (2003) 18:45-49.
57. ENGEL JB, LUDWIG M, FELBERBAUM R, ALBANO C, DEVROEY P, DIEDRICH K: Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? Hum. Reprod. (2002) 17:2022-2026.
58. FAUSER BC, DEVROEY P, YEN SS et al.: Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum. Reprod. (1999) 14:2681-2686.
59. DE JONG D, MacKLON NS, FAUSER BC: A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil. Steril. (2000) 73:1051-1054.
60. HERMANN R, SCHNEIDER E, ROMEIS P: Pharmacokinetics and Ppharmacodynamics of the LHRH antagonist Cetrorelix in healthy male and female subjects. Gynecol. Endocrinol. (1996) 10:18.
61. AL-INANY H, ABOULGHAR M: GnRH antagonist in assisted reproduction: a Cochrane review. Hum. Reprod. (2002) 17:874-885.
62. HERNANDEZ ER: Embryo implantation and GnH antagonists: embryo implantation: the Rubicon for GnRH antagonist. Hum. Reprod. (2000) 15:1211-1216.
63. MANNAERTS B, GORDON K: Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor. Hum. Reprod. (2000) 15:1882-1883.
64. COCCIA ME, COMPARETTO C, BRACCO GL, SCARSELLI G: GnRH antagonists. Eur. J. Obstet. Gynecol. Reprod. Biol. (2004) 1(115 Suppl. 1):S44-S56.
65. LOUTRADIS D, STEFANIDIS K, DRAKAKIS P, MILINGOS S, ANTSAKLIS A, MICHALAS S: A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertil. Steril. (2004) 82:1446-1448.
66. KOLIBIANAKIS E, ALBANO C, ZIKOPOULOS K, KAHN JA, VAN STEIRTEGHEM A, DEVROEY P: GnRH antagonists in poor responders. Acta Obstet. Gynecol. Scand (2004) 83:1216-1217.
67. LUDWIG M, KATALINIC A, DIEDRICH K: Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch. Gynecol. Obstet. (2001) 265:175-182.
68. DAYA S: A comparison of clinical pregnancy rates in the efficacy evaluation of GnRH agonist versus antagonist use for assisted reproduction - a meta-analysis using an intention-to-treat approach. Gynecol. Endocrinol. (2003) 17(Suppl. 1):44.
69. MAHEUX R, LEMAY A, BLANCHET P, FRIEDE J, PRATT X: Maintained reduction of uterine leiomyomata following addition of hormone replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum. Reprod. (1991) 6:500-505.
70. ANONYMOUS: Leuprorelin and triptorelin: new indication. Preoperative treatment of uterine leiomyoma: no proven value. Prescrire Int. (2001) 10:73-77.
71. RUSSO P, CIOLLI P. ATLANTE M, CARICO E et al.: Clinical use of leuprolide acetate depot in a group of gynecological patients in the preoperative period. Minerva Ginecologica (1998) 50:499-502.
72. LETHABY A, VOLLENHOVEN B, SOWTER M: Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database System Review (2001) 2:CD000547.
73. COMPSTON JE, YAMAGUCHI K, CROUCHER PI, GARRAHAN N, LINDSAY PC, SHAW RW. The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone (1995) 16:261-267.
74. KETTEL LM, MURPHY AA, MORALES AJ, RIVIER J, VALE W, YEN SS: Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil. Steril. (1993) 60:642-645.
75. FELBERBAUM RE, GERMER U, LUDWIG M et al.: Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist cetrorelix. Hum. Reprod. (1998) 13:1660-1668.
76. FELBERBAUM RE, KUPKER W, KRAPP W, GEHL B, LUDWIG M, DIEDRICH K: Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotropin-releasing hormone antagonist (Cetrotide). Reprod. Biomed. Online (2001) 3:14-18.
77. YANO T, MINAGUCHI H, TAKETANI Y et al.: Cetrorelix in the treatment of uterine leiomyomas. Gynecol. Endocrinol. (2001) 15:46.
78. DE BLOK S, OBERYE J: Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. Gynecol. Endocrinol. (2001) 15:22.
79. KIESEL L, THOMAS K, TEMPONE A et al.: Efficacy and safety of buserelin treatment in women with endometriosis. Gynecol. Endocrinol. (1998) 3:5-19.
80. KUEPKER W, SCHULTZE-MOSGAU A, DIEDRICH K: Paracrine changes in the peritoneal environment of women with endometriosis. Hum. Reprod. Update (1998) 4:719-723.
81. HUGHES EG, FEDORKOW DM, COLLINS JA: A quantitative overview of controlled trials in endometriosis-associated infertility. Fertil. Steril. (1993) 59:963-970.
82. ADAMSON GD, PASTA DJ: Surgical treatment of endomtriosis-associated infertility: meta-analysis compared with survival analysis. Am. J. Obst. Gynecol. (1994) 171:1488-1505.
83. FERNANDEZ H, LUCAS C, HEDON B, MEYER JL, MAYENGA JM, ROUX C: One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum. Reprod. (2004) 19:1465-1471.
84. TAHARA M, MATSUOKA T, YOKOI T, TASAKA K, KURACHI H, MURATA Y: Treatment of endometriosis with a decreasing dosage of a gonadotrophin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ('draw-back' therapy). Fertil. Steril. (2000) 73:799-804.
85. ROTH C: Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Expert Opin. Investig. Drugs (2002) 11:1253-1259.
86. PAVLOU SN, SHARP SC: Clinical applications of GnRH antagonists in men. In: GnRH, GnRH analogs, gonadotropins ad gonadal peptides. Bouchard P, Carat A, Coelingh Bennink HJT, Pavlou SN (Eds), Parthenon, London (1993):285-292.
87. SPITZ IM, CROXATTO HB, LÄHTEENMÄKI P, HEIKINHEIMO O, BARDIN CW: Effect of mifepristone on inhibition of ovulation and induction of luteolysis. In: Human Reproduction, Progesterone Antagonists in Reproductive Medicine and Oncology. Beier HM, Spitz IM (Eds), Oxford University Press, Oxford, UK (1994) 9(Suppl. 1):69-76.
88. EMONS G, SCHODER B, ORTMANN O, WESTPHALEN S, SCHULZ KD, SCHALLY AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. (1993) 77:1458-1464.
89. YANO T, PINSKI J, HALMOS G, SZEPESHAZI K, GROOT K, SCHALLY AV: Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl. Acad. Sci. USA (1994) 91:7090-7094.
90. EMONS G, SCHULZ KD: Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent Results Cancer Res. (2000) 153:83-94.
91. EMONS G, WEISS S, ORTMANN O, GRUNDKER C, SCHULZ KD: LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur. J. Endocrinol. (2000) 142:665-670.
92. EMONS G, HEYL W: Hormonal treatment of endometrial cancer. J. Cancer Res. Clin. Oncol. (2000) 126:619-623.
93. NOCI I, CORONNELLO M, BORRI P et al.: Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. Cancer Lett. (2000) 150:71-78.
94. EMONS G, GRUNDKER C, GUNTHERT AR, WESTPHALEN S, KAVANAGH J, VERSCHRAEGEN C: GnRH antagonists in the treatment of gynecological and breast cancers. Endocr. Relat. Cancer (2003) 10:291-299.
95. WECKERMANN D, HARZMANN R: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur. Urol. (2004) 46:279-284.
96. TOMERA K, GLEASON D, GITTELMAN M et al.: The Abarelix Study Group. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J. Urol. (2001) 165:1585-1589.
97. GONZALES-BARCENA D, SCHALLY AV, COMARU-SCHALLY AM et al.: Treatment of patients with advanced prostate cancer with LHRH antagonist cetrorelix. In: Treatment with LHRH analogs: controversies and perspectives. Filicori M, Flamigni E (Eds), Parthenon Publishing, London/New York (1996):139-145.
98. McLEOD D, ZINNER N, GLEASON D et al.: Abarelix-depot (A-D) versus leuprolide acetate (L) for prostate cancer: results of a multi-institutional, randomized, Phase III study in 271 patients. Proceedings of the American Society of Clinical Oncology (2000) 19:332a.
99. GARNICK MB, TOMERA K, CAMPION M, KUCA B, GEFTER M: Abarelix-depot (A-D), a sustained-release (SR) formulation of a potent GnRH pure antagonist in patients with prostate cancer (PrCA): Phase II clinical results and endocrine comparison with superagonist Lupton (L) and Zoladex (Z). Proceedings of the American Society of Clinical Oncology (1999) 18:321a.
100. TRACHTENBERG J, FORTHERINGHAM N, CAMPION M, GARNICK M: Avoidance of FSH surge and maintained suppression of follicle-stimulating-hormone (FSH) with abarelix depot (A-D) compared to leuprolide (L) ± bicalutamide in prostate cancer (PC) patients. Proceedings of the American Society of Clinical Oncology (2001) 20:152.
101. GITTELMAN M, GLEAVE M, POMMERVILLE P et al.: Greater and more rapid decrease in prostate specific antigen (PSA) and testosterone (T) levels with abarelix depot (A-D) compared to leuprolide acetate (L): results of a multicenter 24-weeks safety study. Proceedings of the American Society of Clinical Oncology (2001) 20:154.
102. WEISSMAN A, SHOHAM Z: GnRH and its agonistic analogues: basic knowledge. In: Female infertility therapy. Current practice. Shoham Z, Howles C, Jacobs H (Eds) Martin Dunitz Ltd, London, UK (1999):157-166.
103. LAMBERTS SWJ: Testosterone secretion by cultured arrhenoblastoma cells:suppression by luteinizing-hormone agonist. J. Clin. Endocrinol. Metab. (1982) 54:450.
104. GOLAN A, RON-EL R, HERMAN A, WEINTRAUB Z, SOFFER Y, CASPI E: Ovarian hyperstimulation syndrome following D-Trp-6-luteinizing hormone-releasing hormone microcapsules and menotropins for in vitro fertilization. Fertil. Steril. (1988) 50:912-916.
105. SMITZ J, RON-EL R, TARLATZIS BC: The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres. Hum. Reprod. (1992) 7:49-66.
106. SMITZ J, DEVROEY P, FAGUER B, BOURGAIN C, CAMUS M, VAN STEIRTEGHEM AC: A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum. Reprod. (1992) 7:168-175.
107. HWANG JL, SEOW KM, LIN YH et al.: Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum. Reprod. (2004) 19:1993-2000.
108. McCONNELL JD: Prostatic growth: new insights into hormonal regulation. Br. J. Urol. (1995) 76:5-10.
109. McCONNELL JD, WILSON JD, GEORGE FW, GELLER J, PAPPAS F, STONER E: Finasteride, an inhibitor of 5 α-reductase, suppress prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. (1992) 74:505-508.
110. RITTMASTER RS: Finasteride. N. Engl. J. Med. (1994) 330:120-125.
111. KENNY B, BALLARD S, BLAGG J, FOX D: Pharmacological options in the treatment of benign prostatic hyperplasia. J. Med. Chem. (1997) 40:1293-1315.
112. ERI LM, TVETER K: A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J. Urol. (1993) 150(2 Part 1):359-364.
113. ZHU YF, CHEN C: Recent advances in small molecule gonadotropin-releasing hormone receptor antagonists. Expert Opin. Ther. Patents (2004) 14: 187-199
114. ARMER RE, SMELT KH: Non-peptidic GnRH receptor antagonists. Curr. Med. Chem. (2004) 11:3017-3028.
115. JANOVICK JA, MAYA-NUNEZ G, CONN PM: Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J. Clin. Endocrinol. Metab. (2002) 87:3255-3262.
116. TARLATZIS BC, BILI H: Safety of GnRH agonists and antagonists. Expert Opin. Drug. Saf. (2004) 3:39-46.
117. LUDWIG M, KATALINIC A, FELBERBAUM RE, DIEDRICH K: Safety aspects of gonadotropin-relasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born. Reprod. Biomed. Online (2002) 5(Suppl. 1):61-67.